Antibiotic regimens for neonatal sepsis:A protocol for a systematic review with meta-analysis by Korang, Steven Kwasi et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Antibiotic regimens for neonatal sepsis
A protocol for a systematic review with meta-analysis









Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Korang, S. K., Safi, S., Gluud, C., Lausten-Thomsen, U., & Jakobsen, J. C. (2019). Antibiotic regimens for
neonatal sepsis: A protocol for a systematic review with meta-analysis. Systematic Reviews, 8, [306].
https://doi.org/10.1186/s13643-019-1207-1
Download date: 14. maj. 2020
PROTOCOL Open Access
Antibiotic regimens for neonatal sepsis - a
protocol for a systematic review with meta-
analysis
Steven Kwasi Korang1* , Sanam Safi1, Christian Gluud1, Ulrik Lausten-Thomsen2 and Janus C. Jakobsen1,3,4
Abstract
Background: Sepsis is a major cause of morbidity and mortality among neonates and infants. Antibiotics are a
central part of the first line treatment for sepsis in neonatal intensive care units worldwide. However, the evidence
on the clinical effects of the commonly used antibiotic regimens for sepsis in neonates remains scarce. This
systematic review aims to assess the efficacy and harms of antibiotic regimens for neonatal sepsis.
Methods: Electronic searches will be conducted in MEDLINE, Embase, The Cochrane Library, CINAHL, ZETOC and
clinical trial registries (clinicaltrials.gov and ISRCTN). We will include randomised controlled trials of different
antibiotic regimens for sepsis of neonates and infants. Eligible interventions will be any antibiotic regimen. Two
reviewers will independently screen, select, and extract data. The methodological quality of individual studies will
be appraised following Cochrane methodology. Primary outcomes will be ‘all-cause mortality’ and ‘serious adverse
events’. Secondary outcomes will be ‘need for respiratory support’, ‘need for circulatory support’, ‘neurodevelopmental
impairment’, ototoxicity, nephrotoxicity and necrotizing enterocolitis. We plan to perform a meta-analysis with trial
sequential analysis.
Discussion: This is the study protocol for a systematic review on the effects of different antibiotic regimens for
neonatal sepsis. The results of this systematic review intent to adequately inform stakeholders or health care
professionals in the field of neonatal sepsis, and to aid appropriate development of treatment guidelines.
Systematic review registration: PROSPERO reference number: CRD42019134300.
Keywords: Sepsis, Neonates, Infants, Septic shock, Antibiotics, Systematic review
Background
Description of the condition
Definition
Sepsis occurring before 28 days after birth is termed
neonatal sepsis [1, 2]. There is currently no international
consensus on the definition of neonatal sepsis [3, 4].
Most neonatal sepsis criteria used in clinical trials are
based on different combinations of clinical and labora-
tory parameters [4–6].
Due to the lack of consensus on the definition of neo-
natal sepsis, it is difficult to estimate the exact incidence
of neonatal sepsis [1]; however, the incidence is
estimated to be between 1 and 12 per 1000 live births in
high-income countries [1]. The incidence in low- and
middle-income countries is higher, and in Asia, the inci-
dences have been estimated to be up to 38 per 1000 live
births [7–12].
Neonatal sepsis is a major cause of morbidity and
mortality. It is the third leading cause of neonatal mor-
tality and constitutes 13% of overall, global neonatal
mortality [13, 14]. In the high-income countries, neo-
natal sepsis has a mortality ranging from 5 to 20% and
causes major disability (or death) in up to 40% of all
cases despite initiation of conventional treatment [1].
Mortality rates up to 70% have been observed in some
low- and middle-income countries [1, 4, 15, 16].
In survivors, sepsis is associated with serious long-
term morbidity such as cerebral palsy, cognitive and
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psychomotor delay, auditory and visual impairment, and
bronchopulmonary dysplasia [1, 17–19]. Most of these
associations are based on observational cohort studies
and therefore does not distinguish between causality and
association. It remains uncertain whether it is possible
to prevent these subsequent sequela by treating neonatal
sepsis with appropriate empirical antibiotic regimens [1].
Depending on the time of onset, neonatal sepsis may
be divided into early onset sepsis and late onset sepsis.
The most commonly accepted distinction between these
two subgroups is before and after 72 h (but other defini-
tions, e.g. 48 h and 7 days exist) [1, 2, 20–26]. This dis-
tinction is based on the assumed different aetiologies
and pathophysiology of pathogens typically seen before
and after 72 h [2, 22, 27].
The infection in early onset sepsis is usually acquired
vertically from a colonised mother, while the infection in
late onset sepsis is usually acquired horizontally, e.g.
from the community or a nosocomial (hospital-acquired)
infection [16, 22, 26, 28, 29]. However, these theoretical
differences might not warrant a need for different anti-
biotic regimes for early and late onset neonatal sepsis,
especially if broad-spectrum antibiotics are used. Ac-
cordingly, several trials have included both types of neo-
nates without distinguishing between early and late
onset sepsis. As the clinical manifestations also can be
non-specific, it can be hard to clinically distinguish be-
tween sepsis and deep-seated infections such as menin-
gitis, osteomyelitis and necrotizing enterocolitis [2, 26].
The pathogens causing neonatal sepsis include gram-
positive and gram-negative bacteria [30]. The mortality
and the distribution pattern of pathogens causing sepsis
in neonates differs between low- and middle-income
countries and high-income countries. Important patho-
gen variations can sometimes even be seen between in-
dividual neonatal intensive care units (NICUs) within a
given country. Furthermore, the predominant organisms
responsible for neonatal sepsis within regions have also
changed with time [31, 32].
Neonates are theoretically immunocompromised as
several components of the immune system are not fully
developed at birth [2, 33]. This is especially true for pre-
term newborns, as they are additionally immunocom-
promised due to an even more immature immune
system [34–38]. Prematurity and low birth weight are
therefore major risk factors and accordingly, a multi-
centre observational study showed that neonatal sepsis
were most common in premature (82%) and low birth
weight neonates (81%) [39].
Several other risk factors have been shown to be asso-
ciated with an increased risk of developing neonatal sep-
sis [21].
For early onset neonatal sepsis, the risk factors are
multiple gestation, maternal intrapartum fever, maternal
urinary tract infection or chorioamnionitis, prolonged
labour, preterm rupture of the membrane (PROM), pro-
longed PROM > 18 h, and meconium aspiration syn-
drome [27, 40].
Late onset sepsis also has several risk factors such as
mechanical ventilation, intravascular catheterisation, fail-
ure of early enteral feeding with breast milk, a prolonged
duration of parenteral nutrition, surgery, underlying re-
spiratory and cardiovascular diseases, and hospitalisation
[30, 41–44].
Description of the intervention
Treatment of neonatal sepsis is aimed at treating the
underlying infectious cause of sepsis [45, 46], and cor-
recting the associated organic dysfunction through, e.g.
respiratory support, circulatory support and correction
of metabolic, temperature and glucose derangements
[47, 48]. This review assesses the first part, which is to
treat the underlying infectious cause of sepsis.
Preliminary results have shown that early initiation of
antibiotic therapy in neonates with suspected sepsis
seems to reduce both mortality and morbidity [1]. Ac-
cording to guidelines, the treatment should be given as
soon as possible and always within 1 h of the decision to
treat [49]. The antibiotic therapy is empirical and based
on several factors such as age at onset, likely pathogens,
and antibiotic susceptibility patterns [21, 31, 50, 51].
Among the most common types of antibiotics used for
treatment for neonatal sepsis are beta-lactams (e.g. peni-
cillins, cephalosporins, monobactams and carbapenems),
aminoglycosides (e.g. gentamycin) and glycopeptides
(e.g. vancomycin and teicoplanin) [52, 53].
The most commonly recommended and used first-line
treatment for both early and late onset neonatal sepsis is a
beta-lactam antibiotic (most commonly ampicillin, flucloxa-
cillin and penicillin) combined with an aminoglycoside
(most commonly gentamicin) [21, 31, 48, 51, 54–57]. How-
ever, there has been an increased use of alternative proto-
cols using a cephalosporin (most commonly cefotaxime) or
a glycopeptide (most commonly vancomycin) as a first line
option to treat especially late onset sepsis [58–60], due to
increased resistance among the most common pathogen
such as coagulase-negative staphylococci [31, 50]. Ampicil-
lin combined with a third-generation cephalosporin agent
(most commonly cefotaxime) is also used as an alternative
for early onset sepsis [39, 54, 58–60]. Other regimens such
as cephalosporins (as monotherapy) are also used [49].
Guidelines may differ due to local antibiotic resistance of
the most common pathogens or whether the empirical
regimen is supposed to cover the common but low
virulence coagulase-negative staphylococci (for late onset
sepsis) [61, 62]. Vancomycin is often considered if staphylo-
coccal infection is suspected [63].
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The duration of the antibiotic treatment is adjusted ac-
cording to the type of pathogen, treatment response, and
the possibility of the antibiotic to penetrate to the site of
infection in case of, e.g. meningitis, encephalitis, osteo-
myelitis or endocarditis. A prospective observational
study showed that 63% of neonates started in antibiotic
therapy were discontinued within 48 h when cultured
[58]. When and if a pathogen is identified by cultures,
the antibiotic therapy might be changed according to the
antibiotic susceptibility of the pathogen. However, causa-
tive bacteria are identified only in about one-third of the
patients with presumed sepsis [33, 64, 65]. One study
found that the empirical antibiotic regimen was changed
in 44% of the cases when the pathogen and susceptibility
was identified; the most frequently added antibiotics
were vancomycin, cefotaxime and penicillin [39]. It is
recommended to stop the antibiotic treatment when no
signs and symptoms of infection is observed, and no
pathogen is identified [2, 55].
Antibiotic susceptibility
Antibiotic resistance is a global and growing problem
which increases the morbidity, mortality and costs asso-
ciated with infections [57, 66–68]. The bacterial resist-
ance to antibiotics results mainly from the selective
pressure exerted by the use and overuse of antibiotics
[67, 69–72]. Studies, comparing antibiotic susceptibility
over time in the same unit, show increased resistance to
the most used antibiotics [57].
The pathogens causing neonatal infections and their
antibiotic susceptibility patterns change over time and
may differ among countries [57, 73–77]. When compar-
ing the epidemiology of neonatal sepsis in the low- and
middle-income countries with the high-income coun-
tries, some important differences emerge in the pattern
of etiological pathogens and their antibiotic resistance
[11, 78–80].
In high-income countries, data from the UK showed
that 95% of the identified pathogens were susceptible to
the most commonly used empirical antibiotic regimens
of penicillin and gentamicin [54]. In low- and middle-
income countries, estimations suggest that up to 70% of
pathogens isolated from neonatal sepsis may not be cov-
ered by the recommended empirical antibiotic regimen
of ampicillin and gentamicin [81]. Some studies in the
low- and middle-income countries have shown almost
universal antibiotic resistance (92–100% resistant)
among the most common pathogens (gram-negative
rods) to first-line (often ampicillin and gentamicin) and
second-line antibiotics such as the third-generation
cephalosporins [15, 48, 81].
In addition, some low- and middle-income countries face
widespread dissemination of resistant bacterial strains, in-
cluding extended-spectrum-lactamase-producing bacteria
and methicillin-resistant Staphylococcus aureus (MRSA)
[81–84].
Adverse effects
The use of anti-bacterial agents is potentially associated
with adverse effects, but the published data in neonates
are scarce and occasionally contradictory.
The use of ampicillin has in some studies been associ-
ated with adverse effects such as rashes, diarrhoea, nau-
sea and nephrotoxicity [52, 53, 85]. Contrary to these
findings, a recent systematic review of randomised clin-
ical trials showed that ampicillin only increased the inci-
dence of candidiasis with no significant increase in the
abovementioned adverse effects [86]. Nephrotoxicity has
been estimated to be rare (0.03 %) [85].
Aminoglycosides have been shown to be toxic
(nephrotoxic and ototoxic) in adults, whereas its toxicity
in neonates remains unclear [87–95].
The most common adverse effects caused by glycopep-
tides, i.e. vancomycin is fever and phlebitis and in rare
cases nephrotoxicity and ototoxicity [96]. There are lim-
ited data suggesting a direct causal relationship between
toxicity and specific serum vancomycin concentrations
[96]. However, in addition to the development of resist-
ance towards vancomycin some observational studies
also suggest a three- to fourfold increase in nephrotox-
icity when aminoglycosides are combined with vanco-
mycin [96–100].
Cefotaxime is associated with increased risk of
death and invasive candidiasis in non-randomised
studies [59, 63, 101].
In addition to the specific adverse effects of each anti-
biotic, extended use of any antibiotics is also associated
with higher risk of neonatal candidemia [102, 103].
How the intervention might work
Antibiotics are antimicrobial drugs that treat and pre-
vent bacterial infections by either killing (bactericidal) or
inhibiting the growth of the bacteria (bacteriostatic)
[104]. They can be classified based on (1) their mechan-
ism of action (bactericidal or bacteriostatic); (2) bacterial
spectrum (broad or narrow); and (3) chemical structure
(e.g. penicillins, macrolides, quinolones, tetracyclines or
aminoglycosides) [105].
A combination of different antibiotics might have sev-
eral advantages. Firstly, it is thought to provide an en-
hanced effect beyond the additive effects of the
individual therapies [106]. Secondly, it can be used to
broaden the spectrum of antibiotic coverage when used
empirically to increase the chance of covering the pre-
sumed causative bacteria. Thirdly, a combination ther-
apy is thought to suppress the development of
subpopulations of microorganisms resistant to antibi-
otics [106–108].
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However, it is theoretically possible that the optimal
empirical antibiotic treatment should not be chosen
solely based on the presumed pathogen and cultures.
Antibiotics might have different effects in the human
body compared with the pattern they show from in vitro
(cultures).
Why it is important to do this review
Despite the high burden of neonatal sepsis, high-quality
evidence in diagnosis and treatment is scarce [26]. Yet,
in adults, appropriate empirical antibiotic treatment has
been shown to halve the fatality associated with sepsis
compared with inappropriate empirical antibiotic treat-
ment [109–111].
Due to the diagnostic challenges of sepsis and the rela-
tive immunosuppression of the newborn, many neonates
receive antibiotics for suspected sepsis. In fact, antibi-
otics have become the most commonly used pharmaco-
logical therapeutic in neonatal intensive care units [112].
Studies suggest that up to 95% of newborns treated with
antibiotics for suspected sepsis prove to have no evi-
dence of infection [58, 113, 114]. This presumed overuse
of antibiotics seems to contribute to the development
and spread of resistant pathogens in the neonatal inten-
sive care units and seems to be associated with adverse
events (e.g. invasive candidiasis and increased antimicro-
bial resistance) [67, 101, 112, 115–117]. Adverse effects
of antibiotic exposure in infants is believed to be mini-
mised through the appropriate antibiotic choice and
duration of treatment [24].
To create the most appropriate antibiotic policies for
neonatal sepsis, there is a need to base these policies on
an updated systematic review with meta-analysis.
The latest two Cochrane reviews are from 2004 and
2005 and does not include trials not distinguishing be-
tween early and late onset sepsis [118, 119]. Both re-
views concluded that there is inadequate evidence from
randomised trials in favour of any particular antibiotic
regimen for the treatment of suspected early and late
onset neonatal sepsis, respectively [118, 119]. No other
systematic review has been conducted to assess the ef-
fects of different antibiotic regimens for suspected neo-
natal sepsis regardless of onset.
There is therefore a need for a systematic review to as-
sess the effects of different antibiotic regimens for neo-
natal sepsis taking into account both risks of systematic
errors and random errors [120].
Objectives
The objective of this study is to compare the beneficial
and harmful effects of different antibiotic regimens for
neonatal sepsis.
Methods
The present protocol is being reported in accordance with
the reporting guidance the preferred reporting items for
systematic reviews and meta-analyses protocols (PRISMA-
P) statement [121]. This protocol has been registered within
the PROSPERO database (CRD 42019134300).
Criteria for considering studies for this review
Types of studies
Types of studies are randomised clinical trials regardless
of publication type, publication status, publication date,
and language. We will also include quasi-randomised
clinical trials and cluster randomised clinical trials.
Types of participants
Neonates and infants suspected of or diagnosed with
sepsis (as defined by trialists). We will also include neo-
nates and infants (until 3 months of age) suspected of or
diagnosed with severe infections such as meningitis,
osteomyelitis, endocarditis and necrotizing enterocolitis.
Types of interventions
We will accept any type of antibiotic or combination of
antibiotics (regardless of dose and way of administration)
such as the following:
1) Beta-lactam antibiotics
– Narrow-spectrum penicillin antibiotics (e.g.
oxacillin, cloxacillin, dicloxacillin, nafcillin,
methicillin and penicillin G);
– Broad-spectrum penicillin antibiotics (e.g. ampicillin,
amoxicillin, piperacillin, ticarcillin, carbenicillin and
mezlocillin);
– Beta-lactam antibiotics with beta-lactamase inhibi-
tors such as clavulanic acid, sulbactam and
tazobactam;
– Cephalosporins (e.g. cefazolin, cephalexin,
cefuroxime, cefotetan, cefoxitin, ceftriaxone,
cefotaxime, ceftazidime, cefepime, cefazolin,
ceftobiprole and cefoperazone);
– Carbapenems (e.g. imipenem, meropenem,
doripenem and ertapenem) and monobactams (e.g.
aztreonam);
Broad-spectrum penicillins, beta-lactam antibiotics with
beta-lactamase inhibitors, cephalosporins and carbapen-
ems will be considered as broad-spectrum antibiotics.
2) Combination of beta-lactam with aminoglycoside
(e.g. gentamycin)
3) Combination of beta-lactam with glycopeptide
(e.g. vancomycin and teicoplanin)
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4) Combination of glycopeptide with aminoglycoside
We plan to assess the following comparisons:
1. Aminoglycoside added to any type of antibiotic
versus any type of antibiotic (same antibiotic as in
the experimental group).
2. Broad-spectrum beta-lactam antibiotic and
aminoglycoside versus narrow-spectrum beta-
lactam antibiotic (as defined in the above) and
aminoglycoside (same aminoglycoside as in the
experimental group).
3. Beta-lactam antibiotic (as defined in the above) and
aminoglycoside versus beta-lactam antibiotic and
glycopeptide.
4. Any other used antibiotic regimen (not included in
the abovementioned comparisons) versus any other
used antibiotic regimen (not included in the
abovementioned comparisons).
Co-interventions
We will accept any co-intervention provided they are
intended to be delivered similarly to the experimental and
the control group. Assuming no interaction, the effects of
the co-interventions will ‘even out’ in both groups so the
possible effects of antibiotics will be reflected in the
results.
We will exclude trials assessing treatment of fungal
and viral infections.
Types of outcome measures
The primary outcomes are as follows:
1. All-cause mortality.
2. Proportion of participants with a serious adverse
event defined as any untoward medical occurrence
that resulted in death; was life threatening; was
persistent or led to significant disability,
nephrotoxicity, superinfection, need for respiratory
support, need for circulatory support or prolonged
hospitalisation [122]. As we expect the trialists’
reporting of serious adverse events to be
heterogeneous and not strictly according to the
ICH-GCP recommendations, we will include the
event as a serious adverse if the trialists either (1)
use the term ‘serious adverse event’ but not refer to
ICH-GCP or (2) report the proportion of
participants with an event we consider fulfil the
ICH-GCP definition (e.g. myocardial infarction or
hospitalisation). If several of such events are
reported then we will choose the highest proportion
reported in each trial to avoid double counting.
The secondary outcomes are as follows:
1. Need for respiratory support defined as the need for
respiratory support such as non-invasive ventilation
(e.g. CPAP) or invasive ventilation (e.g. respirator)
2. Need for circulatory support defined as the need for
circulatory support such as fluid bolus or vasoactive
medication (e.g. inotropes or vasopressors).
3. Nephrotoxicity (as defined by the trialist).
4. Presence of moderate-to-severe neurological
developmental and sensory impairment (defined as
a functional abnormality in the function of the
brain, spinal cord, muscles, nerves, eyes or ears or
as any significant lag in a child’s physical or motor,
cognitive, behavioural, emotional or social
development, in comparison with other children of
the same age and sex within similar environments.
If formal evaluation tools were used to assess
neurodevelopmental impairment a threshold of − 2
standard deviations of the normal will be used.
Furthermore, severe brain injury per se is included,
such as intraventricular haemorrhage grade 3 and 4
[123, 124] and periventricular leukomalacia.
5. Ototoxicity (as defined by trialist).
6. Necrotizing enterocolitis during or after treatment,
Bells criteria 2 [125].
7. Neurological complication defined as either
intraventricular haemorrhage [126], psychomotor
retardation, or defined by trialist.
All outcomes will be assessed as proportions.
We will use the trial results reported at maximum
follow-up. However, if the trialists report results at mul-
tiple time points, we will primarily use the results re-
ported at the time point closest to 1 year.
Search methods for identification of studies
We will use the criteria and standard methods of
Cochrane and Cochrane Neonatal (see the Cochrane
Neonatal search strategy for specialized register).
Electronic searches
We will conduct a comprehensive search including
Cochrane Central Register of Controlled Trials (CENTRAL,
current issue) in The Cochrane Library; MEDLINE via
PubMed (1996 to current); MEDLINE via Ovid (1946 to
current) Embase (1980 to current); and CINAHL (1982 to
current) using search strategies detailed in Additional file 1.
Further searches will be performed in EMBASE for
pharmaceutical publications and ZETOC for abstracts of
scientific conferences/symposia. References from identi-
fied studies were cross-checked for possible additional
studies.
We will search clinical trials registries for ongoing or
recently completed trials (clinicaltrials.gov; the World
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Health Organization’s International Trials Registry and
Platform, and the ISRCTN Registry).
We will search all databases from their inception to
the present. There will be no restriction by language of
publication, and we will arrange for translation where
necessary. This will be acknowledged in the ‘Acknowl-
edgements’ section.
Searching other resources
We will check reference lists of all relevant primary trials
and reviews for additional references. To identify unpub-
lished trials, we will also search clinical trial registers of
Europe and the USA, websites of pharmaceutical com-
panies, and websites of the US Food and Drug Adminis-
tration (FDA) and the European Medicines Agency.
Data collection
Selection of studies
Two review authors (SKK and SS) will independently
screen titles and abstracts. We will retrieve all relevant
full-text study reports/publication and two review au-
thors (SKK and SS) will independently screen the full
texts and identify trials for inclusion and identify and
record reasons for exclusion of the ineligible studies. We
will resolve any disagreement through discussion or, if
required, by consulting a third person (JCJ). We will rec-
ord the selection process in sufficient detail to complete
a PRISMA flow diagram [127] and “Characteristics of
excluded studies” table.
Data extraction and management
We will use data collection forms for trial characteristics
and outcome data which has been piloted on at least
one trial in the review. Two review authors (SKK and
SS) will extract trial characteristics from included trials.
We will extract the following trials characteristics:
1. Methods—trial design, total duration of the trial,
number of trial centres and location, trial setting,
bias domain items, withdrawals and date of the
trial.
2. Participants—number of participants in each
intervention group, mean age, age range, sex,
diagnostic criteria, inclusion criteria and exclusion
criteria.
3. Interventions—intervention and comparison.
4. Outcomes—primary and secondary outcomes
specified and collected and time points reported.
5. Notes—funding for trial, and notable conflicts of
interest of trial authors.
Two review authors (SKK and SS) will independently
extract outcome data from included trials. We will note in
the ‘Characteristics of included studies’ table if outcome
data were not reported in a usable way. We will resolve
disagreements by consensus or by involving a third person
(JCJ). We will double-check that data are entered correctly
by comparing the data presented in the systematic review
with the study reports. A second review author (SS) will
spot-check study characteristics for accuracy against the
trial report.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias
(low, high or unclear) of all included trials using the
Cochrane ‘Risk of bias’ tool [128] for the following domains.
Allocation sequence generation
 Low risk: If sequence generation was achieved using
computer random number generator or a random
numbers table. Drawing lots, tossing a coin,
shuffling cards and throwing dice were also
considered adequate if performed by an independent
adjudicator.
 Unclear risk: If the method of randomisation was
not specified but the trial was still presented as
being randomised.
 High risk: If the allocation sequence was not
randomised or only quasi-randomised.
Allocation concealment
 Low risk: If the allocation of patients was performed
by a central independent unit, on-site locked com-
puter, identical-looking numbered sealed envelopes,
drug bottles or containers prepared by an independ-
ent pharmacist or investigator.
 Uncertain risk: If the trial was classified as
randomised but the allocation concealment process
was not described.
 High risk: If the allocation sequence was familiar to
the investigators who assigned participants.
Blinding of participants and treatment providers
 Low risk: If the participants and the treatment
providers were blinded to intervention allocation,
and this was described.
 Uncertain risk: If the procedure of blinding was
insufficiently described.
 High risk: If blinding of participants and the
treatment providers was not performed.
Blinding of outcome assessment
 Low risk of bias: If it was mentioned that outcome
assessors were blinded and this was described.
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 Uncertain risk of bias: If it was not mentioned if the
outcome assessors in the trial were blinded, or the
extent of blinding was insufficiently described.
 High risk of bias: If no blinding or incomplete
blinding of outcome assessors was performed.
Incomplete outcome data
 Low risk of bias: If missing data were unlikely to
make treatment effects depart from plausible values.
This could either be (1) there were no dropouts or
withdrawals for all outcomes or (2) the numbers and
reasons for the withdrawals and dropouts for all
outcomes were clearly stated and could be described
as being similar in both groups. Generally, the trial
was judged as at a low risk of bias due to incomplete
outcome data if dropouts were less than 5%.
However, the 5% cutoff was not definitive.
 Uncertain risk of bias: If there was insufficient
information to assess whether missing data were
likely to induce bias on the results.
 High risk of bias: If the results were likely to be
biased due to missing data either because the
pattern of dropouts could be described as being
different in the two intervention groups or the trial
used improper methods in dealing with the missing
data (e.g. last observation carried forward).
Selective outcome reporting
 Low risk of bias: If a protocol was published before
or at the time the trial was begun and the outcomes
specified in the protocol were reported on. If there
was no protocol or the protocol was published after
the trial was begun, reporting of all-cause mortality
and serious adverse events would grant the trial a
grade of low risk of bias.
 Uncertain risk of bias: If no protocol was published
and the outcomes all-cause mortality and serious ad-
verse events were not reported on.
 High risk of bias: If the outcomes in the protocol
were not reported on.
For-profit bias
 Low risk of bias: If the trial was not financed by a
company that might have an interest in a given
result.
 Uncertain risk of bias: If there was no description of
how the trial was financed.
 High risk of bias: If the trial was financed or have
other involvement by a company that might have an
interest in a given result.
Other bias
 Low risk of bias: The trial appeared to be free of
other bias domains (e.g. academic) that could put it
at risk of bias.
 Unclear risk of bias: The trial may or may not have
been free of other domains that could put it at risk
of bias.
 High risk of bias: There were other factors in the
trial that could put it at risk of bias (e.g. authors
have conducted trials on the same topic).
Overall risk of bias
We assessed overall risk of bias in two groups defined
as:
 Low risk of bias: The outcome result was classified
as overall ‘low risk of bias’ only if all of the bias
domains described in the above paragraphs were
classified as low risk of bias.
 High risk of bias: The outcome result was classified
‘high risk of bias’ if any of the bias risk domains
described in the above excluding ‘blinding of
participants and personnel’ were classified as
‘unclear’ or ‘high risk of bias’.
 Any other bias
Any disagreements will be resolved by discussion or by
a third assessor. Our primary conclusions will be based
on the results of our primary outcomes at overall low
risk of bias. The bias risk assessment enable classifica-
tion of randomised trials with low risk of bias and high
risk of bias. The latter trials tend to overestimate positive
intervention effects and underestimate negative effects
[129–133].
Data synthesis
Measures of treatment effect
Dichotomous outcomes
We will calculate risk ratios (RRs) with 95% confidence
interval (CI) for dichotomous outcomes.
Unit of analysis issues
The unit of analysis will be the participating infant in in-
dividually randomised trials and the neonatal unit (or
sub-unit) for cluster-randomised trials. For cluster-
randomised trials, we will undertake analyses at the level
of the individual while accounting for the clustering in
the data using the methods recommended in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [134].
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Dealing with missing data
We will not impute missing values for any outcomes in
our primary analysis. In two of our sensitivity analyses,
we will impute data (see ‘Sensitivity analysis’).
We will contact investigators and trial sponsors in
order to verify key trial characteristics and obtain miss-
ing numerical outcome data where possible (e.g. when a
study is identified as abstract only).
Assessment of heterogeneity
We will visually inspect forest plots to assess signs of
heterogeneity, and we will explore possible heterogeneity
in our prespecified subgroup analyses. We will also in-
spect trial characteristics across trials to identify clinical
heterogeneity. We will assess the presence of statistical
heterogeneity by the χ2 test (threshold P < 0.10) and
measure the quantities of heterogeneity by the I2 statistic
[135, 136]. If we detect moderate or high heterogeneity,
we plan to explore the possible causes (e.g. differences in
study design, participants, interventions or completeness
of outcome assessments). Ultimately, we may decide that
a meta-analysis should be avoided [134].
Meta-analysis
We will undertake this meta-analysis according to the
recommendations stated in the Cochrane Handbook for
Systematic Reviews of Interventions [134]. We will use
the statistical software Review Manager 5 [137] provided
by Cochrane to analyse data.
We will assess our intervention effects with both
random-effects model meta-analyses [138] and fixed-
effect model meta-analyses [120, 139]. We will use the
more conservative point estimate of the two [120]. We
consider ‘the more conservative point estimate’, the esti-
mate closest to zero effect [120]. If the two estimates are
equal, we will use the estimate with the widest CI [120].
We will use two primary outcomes, and, therefore, we
will consider a P value of 0.033 or less as the threshold
for statistical significance [120]. For all remaining out-
comes, we will consider a P value of 0.05 or less as the
threshold for statistical significance [120]. We will use
the eight-step procedure to assess if the thresholds for
significance are crossed [120]. Our primary conclusion
will be based on results with low risk of bias [120].
Where data are only available from one trial, we will use
Fisher’s exact test [140] for dichotomous data.
Where multiple trial arms are reported in a single trial,
we will include only the relevant arms. If two compari-
sons are combined in the same meta-analysis, we will
halve the control group to avoid double counting.
Trial sequential analysis
Traditional meta-analysis (TSA) runs the risk of random
errors due to sparse data and repetitive testing of
accumulating data when updating reviews. We will
therefore perform trial sequential analyses on the out-
comes, in order to calculate the required information
size and the cumulative Z curve’s breach of relevant trial
sequential monitoring boundaries [141–147]. We wish
to control the risks of type I errors and type II errors. A
more detailed description of trial sequential analysis can
be found at http://www.ctu.dk/tsa/. We will assess our
trial sequential analysis intervention effects with both a
random effects model [138] and a fixed-effect model
[139]. We will use the more conservative point estimate
of the two [120]. The more conservative point estimate
will be the estimate closest to zero effect. If the two esti-
mates are similar, we will use the estimate with the wid-
est CI.
For dichotomous outcomes, we will estimate the re-
quired information size based on the observed, un-
weighted proportion of patients with an outcome in the
control group (the cumulative proportion of patients
with an event in the control groups relative to all pa-
tients in the control groups), a relative risk reduction of
20%, an alpha of 3.3%, a beta of 20% and diversity as
suggested by the trials in the meta-analysis.
Meta-bias
We will use a funnel plot to assess publication bias if ten
or more trials are included. We will visually inspect funnel
plots to assess the risk of bias. As we plan to report results
when analysing dichotomous outcomes using risk ratios,
we will not use any test to assess funnel plot asymmetry
when analysing dichotomous outcomes [134].
Assessment of bias in conducting the systematic review
We will conduct the review according to this published
protocol and report any deviations from it in the ‘Differ-
ences between protocol and review’ section of the sys-
tematic review.
‘Summary of findings’ table and GRADE
We will create a ‘Summary of Findings’ table using each
of the prespecified primary outcomes and five prespeci-
fied secondary outcomes (respiratory failure, circulatory
failure, nephrotoxicity, neurological complication and
ototoxicity) at maximum follow-up. We will use the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach, as outlined in the
GRADE Handbook [148] to assess the certainty of the
body of evidence for our primary outcomes.
Two authors will independently assess the quality of
the evidence for each of the outcomes above. We will
consider evidence from randomized controlled trials as
high quality but downgrade the evidence one level for
serious (or two levels for very serious) limitations based
upon the following: design (risk of bias), consistency
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across studies, directness of the evidence, precision of
estimates and presence of publication bias. We will as-
sess ‘precision of estimates’ using TSA [120]. We will
use the [149] Guideline Development Tool to create a
‘Summary of findings’ table to report the quality of the
evidence.
The GRADE approach results in an assessment of the
quality of a body of evidence in one of four grades:
1. High: We are very confident that the true effect lies
close to that of the estimate of the effect.
2. Moderate: We are moderately confident in the
effect estimate: the true effect is likely to be close to
the estimate of the effect, but there is a possibility
that it is substantially different.
3. Low: Our confidence in the effect estimate is
limited: the true effect may be substantially different
from the estimate of the effect.
4. Very low: We have very little confidence in the
effect estimate: the true effect is likely to be
substantially different from the estimate of effect.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses
for our primary outcomes.
1. High risk of bias trials compared with low risk of
bias trials.
2. Trials assessing neonatal sepsis without separation
between early and late onset sepsis compared to
separation at either 48 h, 72 h or 7 days.
3. Gestational age: term (≥ 37 weeks) compared with
preterm
4. Trials from high-income countries compared with
trials from low- and middle-income countries as de-
fined by the World Bank [150]
5. Route of administration such as either oral,
intramuscular or intravenous
We will use the formal test for subgroup interactions
in Review Manager [137].
Sensitivity analysis
To assess the potential impact of the missing data, we
will perform the two following sensitivity analyses on the
primary outcomes.
 ‘Best-worst-case’ scenario: we will assume that all
participants lost to follow-up in the experimental
group have survived and had no serious adverse
event, and all those participants with missing
outcomes in the control group have not survived
and have had a serious adverse event.
 “Worst-best-case’ scenario. we will assume that all
participants lost to follow-up in the experimental
group have not survived and have had a serious
adverse event and that all those participants lost to
follow-up in the control group had survived and had
no serious adverse event.
We will present results of both scenarios in our review.
Other post-hoc sensitivity analyses might be warranted
if unexpected clinical or statistical heterogeneity is iden-
tified during the analysis of the review results [120].
Discussion
This protocol has several methodological strengths. First,
this will be a systematic review that includes neonates
with both early and late onset neonatal sepsis, which in-
creases the statistical power and may lead to conclusive
results. Second, our methodology is described in detail
in this protocol which will be published before the litera-
ture search is initiated. Third, we will conduct the review
based on the Cochrane Handbook and findings and rec-
ommendation of additional methodological studies [120,
135]. Hence, we will systematically assess the risks of
systematic errors via bias risk assessments, and we will
conduct trial sequential analyses and properly adjust our
thresholds for statistical significance to control the risks
of random error. This adds further robustness to our re-
sults and hence to our conclusions [151]. Forth, we will
use our systematic eight step procedure to assess if the
thresholds for statistical and clinical significance are
crossed [120].
Neonatal sepsis and sepsis among infants are syn-
dromes with high clinical heterogeneity and without
internationally agreed upon diagnostic criteria. The
underlying bacteria causing sepsis are expected to differ
in the different trials as we include trials regardless of
onset (in the neonatal period) and location (country).
The doses and length of therapy of the antibiotic regi-
mens might also differ between trials, and the trials we
will include will possibly use different inclusion criteria.
Therefore, the clinical heterogeneity between the trials
might be relatively high. This expected heterogeneity
may cause significant differences in mortality rates
among different trials. In addition, there might be sub-
stantial differences in the types of serious adverse events
the trials report, which may compromise the validity of
the serious adverse event outcome. Also, it is possible
that there exist temporospatial differences in other ele-
ments of sepsis treatment that may lead to potential dif-
ferences in results among different trials. We plan to
carefully consider these potential limitations in the main
publication. We do not expect to include a large number
of relevant trials, which potentially will limit the statis-
tical power of this review.
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